Publications by authors named "D C F Klatte"
Automated volumetric segmentation of the pancreas on cross-sectional imaging is needed for diagnosis and follow-up of pancreatic diseases. While CT-based pancreatic segmentation is more established, MRI-based segmentation methods are understudied, largely due to a lack of publicly available datasets, benchmarking research efforts, and domain-specific deep learning methods. In this retrospective study, we collected a large dataset (767 scans from 499 participants) of T1-weighted (T1 W) and T2-weighted (T2 W) abdominal MRI series from five centers between March 2004 and November 2022.
View Article and Find Full Text PDFPancreatic cancer surveillance: Risk stratification of individuals with a germline CDKN2A pathogenic variant.
United European Gastroenterol J
December 2024
Background: Individuals carrying a germline CDKN2A pathogenic variant (PV) are at a high risk of developing pancreatic ductal adenocarcinoma. Risk stratification could allow tailored surveillance.
Objective: To develop a Fine-Gray prediction model for the risk of PDAC in carriers of a CDKN2A PV.
Article Synopsis
- A multicenter study aimed to evaluate the effectiveness of methylated DNA markers (MDMs) found in pancreatic juice (PJ) for detecting pancreatic ductal adenocarcinoma (PDAC) when used alone and in combination with a blood test, CA 19-9.
- The analysis included DNA samples from 88 confirmed PDAC cases and 134 control cases, utilizing logistic regression to summarize accuracy through the area under the receiver-operating characteristic curve (AUROC).
- Results showed that the combination model of PJ-MDMs and CA 19-9 achieved a higher accuracy (AUROC of 0.95) compared to using PJ-MDMs (0.87) or CA 19-9 alone (0
Individuals with a germline CDKN2A pathogenic variant (PV) have a highly increased life time risk of melanoma and pancreatic cancer. This cross-sectional study assessed the attitudes among toward genetic testing, family planning, and preimplantation genetic testing (PGT) in confirmed CDKN2A PV carriers and individuals with a 50% risk of the PV (at-risk carriers) using of a one-time questionnaire.A total of 537 individuals were screened for eligibility, of whom 208 of 366 (57%) confirmed carriers (56% female, median age 54 years [IQR 46-63]) and 39 of 171 (23%) at-risk carriers (59% female, median age of 26 years [IQR 22-32]) participated in the study.
View Article and Find Full Text PDFTemporal Trends in Body Composition and Metabolic Markers Prior to Diagnosis of Pancreatic Ductal Adenocarcinoma.
Clin Gastroenterol Hepatol
September 2024
Background & Aims: Changes in body composition and metabolic factors may serve as biomarkers for the early detection of pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to capture the longitudinal changes in body composition and metabolic factors before diagnosis of PDAC.
Methods: We performed a retrospective cohort study in which all patients (≥18 years) diagnosed with PDAC from 2002 to 2021 were identified.